Who is sponsoring NCT02871375?

NCT02871375 is sponsored by Alcon, a Novartis Company.

What drugs are being tested in NCT02871375?

Interventions in NCT02871375: Delefilcon A multifocal contact lenses, Habitual multifocal contact lenses.

What condition does NCT02871375 study?

NCT02871375 studies Refractive Error.

Is NCT02871375 still recruiting?

NCT02871375 is currently completed. Last updated 2 July 2018.

Are results published for NCT02871375?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-07-02 · How we verify

NCT02871375

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Assessment of DAILIES TOTAL1® (DT1) Multifocal

Completed NA Results posted Last updated 2 July 2018

What this trial tests

NA trial testing Delefilcon A multifocal contact lenses in Refractive Error in 170 participants. Completed in 14 November 2016.

Timeline

30 August 2016

Primary endpoint
14 November 2016

14 November 2016

Quick facts

Lead sponsor	Alcon, a Novartis Company
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	single
Primary purpose	treatment
Enrollment	170
Start date	30 August 2016
Primary completion	14 November 2016
Estimated completion	14 November 2016

Drugs / interventions tested

Delefilcon A multifocal contact lenses
Habitual multifocal contact lenses

Conditions studied

Refractive Error — all drugs for Refractive Error →

Sponsor

Alcon, a Novartis Company — full company profile →

Who can join

Adults 40 to 65, any sex, with Refractive Error. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Binocular High Contrast/High Illumination (HC/HI) Visual Acuity (VA) at Intermediate Distance (80 cm) Primary · Day 14, each product

Visual Acuity (clarity or sharpness of vision) was measured at high contrast level. HC/HI VA was assessed binocularly (both eyes together) at 80 centimeters using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart and measured in logarithm of the minimum angle of resolution (logMAR). A lower logMAR value indicates better visual acuity.

Group	Value	95% CI
DT1 MF	-0.07	± 0.10
Habitual MF	-0.09	± 0.10

Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) Score Secondary · Day 14, each product

The abbreviated CLDEQ-8 is an 8-item questionnaire used to assess comfort and dryness. Total CLDEQ-8 score ranged from 0 to 37, where a lower score represented less symptomology.

Period One

Group	Value	95% CI
DT1 MF	9.9	± 5.4
Habitual MF	17.0	± 7.1

Period Two

Group	Value	95% CI
DT1 MF	11.6	± 6.3
Habitual MF	13.0	± 6.2

Overall

Group	Value	95% CI
DT1 MF	10.7	± 5.9
Habitual MF	14.9	± 6.9

Sponsor's own description

The purpose of this study is to evaluate DAILIES TOTAL1® Multifocal (DTl MF) contact lenses in current multifocal contact lens wearers with symptoms of end of day discomfort compared to their habitual multifocal contact lens correction.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Delefilcon A multifocal contact lenses

Trials testing the same drug.

NCT03341923 — Clinical Evaluation of DAILIES TOTAL 1® Multifocal Compared to 1-Day Acuvue® Moist® Multifocal in a Japanese Population · NA · completed
NCT03118934 — Assessing Fitting Guides in Alcon Multifocal Contact Lenses · NA · completed

Other recruiting trials for Refractive Error

Currently open trials in the same condition.

NCT07354945 — An Evaluation of Myopia Control Lenses on Wearing Experience in Myopic Children · NA · recruiting

Other Alcon, a Novartis Company trials

Trials by the same sponsor.

NCT02987660 — Comparison of Topography Guided LASIK With WaveLight® EX500 to SMILE With Zeiss VisuMax · NA · terminated
NCT02974140 — Cataract Refractive Suite Study · NA · terminated
NCT03026257 — Clinical Assessment of a HYDRAGLYDE® Regimen · NA · completed
NCT02965820 — OPTI-FREE® PureMoist® for Presbyopic Contact Lens Wearers · NA · completed
NCT02965833 — CLEAR CARE® PLUS for Presbyopic Contact Lens Wearers · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02871375 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alcon, a Novartis Company
Last refreshed: 2 July 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02871375.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing